Stimuvax BLP25 Liposome Vaccine Clinical Program Temporarily Suspended, Suspected Unexpected Serious Adverse Reaction
Links shared publicly online about this topic.
- 1,293total visits
Stimuvax BLP25 Liposome Vaccine Clinical Program Temporarily Suspended, Suspected Unexpected Serious Adverse Reaction
Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. announced that they have temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in
View full resource at medicalnewstoday.com
Tags: Vaccination, Vaccine, Merck & Co., Merck KGaA
Most Recently Shared on March 26, 2010 at 7:18 pm By:
Stimuvax (cancer vaccine) trials, including 1 in #lungcancer, suspended after pt in myeloma trial develops encephalitis: http://is.gd/b0Mq5
Also Shared By:
Advertisement
medical_tweets
@medical_tweets
Stimuvax BLP25 Liposome Vaccine Clinical Program Temporarily Suspended, Suspected Unexpected Serious Adverse Reaction.. http://bit.ly/bIYimd
2 years ago...